WO2025240818 - AGONISTS OF 8-OXO-GUANINE DNA GLYCOSYLASE
National phase entry is expected:
Publication Number
WO/2025/240818
Publication Date
20.11.2025
International Application No.
PCT/US2025/029690
International Filing Date
16.05.2025
Title **
[English]
AGONISTS OF 8-OXO-GUANINE DNA GLYCOSYLASE
[French]
AGONISTES DE L'ADN GLYCOSYLASE 8-OXO-GUANINE
Applicants **
OREGON HEALTH & SCIENCE UNIVERSITY
Inventors
LLOYD, R. Stephen
McCULLOUGH, Amanda K.
MINKO, Irina G.
NILSEN, Aaron
Priority Data
63/648,623
16.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2979 | |
| EPO | Filing, Examination, Granting | 16940 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 2463 | |
| USA | Filing, Examination, Granting | 4760 |
Total:
29,449
Contact Us
Abstract[English]
The present invention is directed to substituted 1-(1H-imidazol-1-yl)-3-methyl-2- phenylbutan-2-ol and 1-cyclopentyl-2-(1H-imidazol-1-yl)-1-phenylethan-1-ol compounds useful as agonists of 8-oxo-guanine DNA glycosylase (OGG1) in humans, as well as pharmaceutical compositions comprising them and methods of their use in treating diseases, including metabolic syndrome, obesity, fatty liver disease, dyslipidemia, insulin resistance, neurodegenerative disorders and cancers.[French]
La présente invention concerne des composés 1-(1H-imidazol-1-yl)-3-méthyl-2-phénylbutan-2-ol et 1-cyclopentyl-2-(1H-imidazol-1-yl)-1-phényléthan-1-ol substitués utiles en tant qu'agonistes de l'ADN glycosylase 8-oxo-guanine (OGG1) chez l'être humain, ainsi que des compositions pharmaceutiques les comprenant et leurs procédés d'utilisation dans le traitement de maladies, y compris le syndrome métabolique, l'obésité, la stéatose hépatique, la dyslipidémie, la résistance à l'insuline, les troubles neurodégénératifs et les cancers.